Compare PKOH & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKOH | SLDB |
|---|---|---|
| Founded | 1907 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.6M | 623.0M |
| IPO Year | 1994 | 2017 |
| Metric | PKOH | SLDB |
|---|---|---|
| Price | $44.85 | $6.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | ★ $59.00 | $18.71 |
| AVG Volume (30 Days) | 72.8K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $1,599,100,000.00 | $8,094,000.00 |
| Revenue This Year | $7.26 | N/A |
| Revenue Next Year | $3.99 | N/A |
| P/E Ratio | $19.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.69 | $4.16 |
| 52 Week High | $53.30 | $11.45 |
| Indicator | PKOH | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 52.16 |
| Support Level | $43.76 | $6.76 |
| Resistance Level | $48.74 | $7.42 |
| Average True Range (ATR) | 2.89 | 0.51 |
| MACD | 0.32 | 0.17 |
| Stochastic Oscillator | 53.64 | 54.78 |
Park-Ohio Holdings Corp is a diversified international company offering its clients supply chain management outsourcing services, capital equipment used on their production lines, and manufactured components used to assemble their products. The company operates through three reportable segments: Supply Technologies, Assembly Components, and Engineered Products. Maximum revenue is generated from the Supply Technologies segment, which is mainly engaged in sourcing, planning, and procurement of several production components, including fasteners, pins, nuts, bolts, valves, hoses, wire harnesses, clamps and fittings, etc. Geographically, the company generates maximum revenue from its business in the United States, followed by Europe, Asia, Mexico, Canada, and other regions.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.